Sonnet BioTherapeutics Holdings, Inc.
SONN
$1.16
-$0.0087-0.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 977.59% | 673.99% | -87.42% | -67.76% | -53.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 977.59% | 673.99% | -87.42% | -67.76% | -53.27% |
| Cost of Revenue | 123.09% | 145.34% | -9.82% | -135.19% | -125.25% |
| Gross Profit | -101.46% | -111.30% | -442.26% | 135.97% | 126.04% |
| SG&A Expenses | 42.01% | 26.64% | -13.96% | -22.17% | -32.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.88% | -1.15% | -37.34% | -45.78% | -52.26% |
| Operating Income | -8.83% | 7.19% | 36.95% | 45.61% | 52.25% |
| Income Before Tax | -55.79% | 35.88% | 60.51% | 64.65% | 68.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.67% | 34.78% | 60.51% | 64.65% | 68.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.67% | 34.78% | 60.51% | 64.65% | 68.23% |
| EBIT | -8.83% | 7.19% | 36.95% | 45.61% | 52.25% |
| EBITDA | -8.84% | 7.19% | 36.97% | 45.63% | 52.28% |
| EPS Basic | 73.12% | 90.49% | 95.56% | 95.36% | 94.83% |
| Normalized Basic EPS | 73.30% | 90.56% | 95.56% | 95.36% | 94.83% |
| EPS Diluted | 73.14% | 90.45% | 95.55% | 95.35% | 94.83% |
| Normalized Diluted EPS | 73.33% | 90.53% | 95.55% | 95.35% | 94.83% |
| Average Basic Shares Outstanding | 422.34% | 336.67% | 404.64% | 484.48% | 686.55% |
| Average Diluted Shares Outstanding | 410.45% | 340.18% | 411.09% | 494.77% | 704.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |